Loading…
Loading…
SPC (CrossingBridge Pre-Merger SPAC ETF) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
See exactly how SPC's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SPC and 80,000+ other tickers.
The CrossingBridge Pre-Merger SPAC ETF operates as an actively managed exchange-traded fund. Typically, it dedicates a minimum of 80% of its investable capital, including any funds acquired through borrowing, to equity and unit interests of Special Purpose Acquisition Companies (SPACs). The fund specifically targets SPACs that have not yet completed a shareholder-approved merger or business combination. Its strategy focuses on acquiring shares of publicly listed SPACs that, at the point of purchase, are trading at a price equal to or less than the pro-rata cash held within the SPAC's trust account. This fund is structured as a non-diversified investment vehicle.
Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system
Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has confirmed the physical, chemical and microbiological stability of its investigational soft-mist intranasal prophylactic, SPC-15, through nine months of real-time testing.
SARASOTA, FL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel intranasal therapeutic targeting Post-Traumatic Stress Disorder (PTSD). The allowed application, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior,” strengthens Silo's growing intellectual-property portfolio in stress-modulating therapeutics and supports the Company's strategy to protect its core scientific innovations in key global markets.
Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a diversified developmental stage biopharmaceutical and cryptocurrency treasury company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced it has entered into a non-binding Letter of Intent (“LOI”) with Allucent (US) LLC (“Allucent”), a global clinical research organization (CRO), to provide clinical research services for two planned Phase 1 studies evaluating its SPC-15 nasal spray in healthy subjects: an Open-Label, Single Ascending Dose (SAD) study and an Open-Label, Multiple Ascending Dose (MAD) study. Allucent and Silo intend to negotiate a Master Services Agreement and project-specific Work Order to cover a comprehensive scope of activities across clinical operations, pharmacovigilance, data management, biostatistics, clinical pharmacology modeling & simulation, and medical writing to support execution and reporting of the Phase 1 program.
SPC Financial Inc. lowered its stake in shares of NVIDIA Corporation (NASDAQ: NVDA) by 3.2% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 29,685 shares of the computer hardware maker's stock after selling 970 shares during the period. SPC Financial Inc.'s holdings in NVIDIA